Therapeutic approaches for the treatment of genetic and acquired cardiovascular calcification
Authors:
Open Access
- 7 October 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1636432
Abstract
Vascular calcification, the deposition of calcium-phosphate crystals in the vasculature, occurs through a complex interplay between cellular processes and biochemical factors that are yet to be entirely defined. Vascular calcification results in stiffening of the arteries and ultimately cardiovascular complications. Deposition can occur either in the intima or media layers of a vasculature through discrete mechanisms and underlying pathologies. Medial calcification, the subject of this review, occurs in a specific set of pathologies including genetic disorders, diabetes, and chronic kidney disease. There are currently no approved therapies for prevention of medial vascular calcification leaving this an active area of unmet therapeutic need. One of the key molecule involved in preventing vascular calcification is pyrophosphate (PPi), long known as a potent inhibitor of mineralization. Many therapeutic avenues, both historical and current, have focused on increasing the plasma concentration of PPi. This can be accomplished by direct PPi supplementation or by use of bisphosphonates, acting as non-hydrolysable PPi analogs, though both approaches have limitations. Newer therapies utilize recombinant ENPP1, which generates PPi by hydrolysis of endogenous ATP, an approach which is currently being evaluated in clinical trials. Another approach to elevate plasma PPi concentration is by preventing enzymatic degradation of PPi through inhibition of alkaline phosphatase. Alternatively, chelation of either phosphate or calcium, the key constituent minerals of calcification, using phosphate binders represent other approaches as well as the use of magnesium and vitamin K supplementation. This review will first briefly discuss the pathophysiology of medial vascular calcification and describe the disease conditions involved before surveying the different therapeutic interventions evaluated to address the medial vascular calcification in the setting of genetic diseases as well as chronic diseases. We will present a bench to bedside view of development discussing therapeutic evidence in animal models, clinical trials and their relevance and applicability to clinical development.Keywords
This publication has 93 references indexed in Scilit:
- The Mineralization Regulator ANKH Mediates Cellular Efflux of ATP, Not PyrophosphateJournal of Bone and Mineral Research, 2022
- Ectopic Calcification and Hypophosphatemic Rickets: Natural History of ENPP1 and ABCC6 DeficienciesJournal of Bone and Mineral Research, 2021
- In Vitro and In Vivo Pharmacological Profiles of DS-1211, a Novel Potent, Selective, and Orally Bioavailable Tissue-Nonspecific Alkaline Phosphatase InhibitorJournal of Bone and Mineral Research, 2020
- INZ-701 Prevents Ectopic Tissue Calcification and Restores Bone Architecture and Growth in ENPP1-Deficient MiceJournal of Bone and Mineral Research, 2020
- From membrane to mineralization: the curious case of the ABCC6 transporterFEBS Letters, 2020
- Inhibition of tissue‐nonspecific alkaline phosphatase protects against medial arterial calcification and improves survival probability in the CKD‐MBD mouse modelThe Journal of Pathology, 2019
- Signaling pathways involved in vascular smooth muscle cell calcification during hyperphosphatemiaCellular and Molecular Life Sciences, 2019
- Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)Cochrane Database of Systematic Reviews, 2018
- Pathophysiological Role of Vascular Smooth Muscle Alkaline Phosphatase in Medial Artery CalcificationJournal of Bone and Mineral Research, 2014
- Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancyJournal of Bone and Mineral Research, 2012